SCHEMBL22897286

SCHEMBL22897286

CCOC(=O)c1cc(Cl)sc1-c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM6 O15303 5/20 0.59
ALDH1A1 P00352 9/20 0.56
HPGD P15428 8/20 0.56
MAPT P10636 5/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
HSD17B10 Q99714 3/20 0.56
GAA P10253 2/20 0.56
RAB9A P51151 2/20 0.56
ALOX15 P16050 1/20 0.56
NPSR1 Q6W5P4 2/20 0.52
TSHR P16473 3/20 0.51
LMNA P02545 1/20 0.50
KDM4E B2RXH2 2/20 0.49
MEN1 O00255 1/20 0.49
NPC1 O15118 1/20 0.49
KMT2A Q03164 1/20 0.49
TP53 P04637 1/20 0.48
THRB P10828 1/20 0.48
GSTO1 P78417 1/20 0.47
CDC7 O00311 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20028742 0.85 ALDH1A1 (0.58) GRM6ALDH1A1HPGDMAPTSMN1; SMN2
SCHEMBL976420 0.84 ALDH1A1 (0.72) GRM6ALDH1A1HPGDMAPTSMN1; SMN2
SCHEMBL3316342 0.84 MAPT (0.52) GRM6ALDH1A1HPGDMAPTSMN1; SMN2
SCHEMBL20028533 0.83 ALDH1A1 (0.56) GRM6ALDH1A1HPGDMAPTSMN1; SMN2
SCHEMBL13398578 0.83 GAA (0.58) GRM6ALDH1A1HPGDMAPTSMN1; SMN2
SCHEMBL29790244 0.81 GRM6 (0.44) GRM6ALDH1A1HPGDMAPTSMN1; SMN2
SCHEMBL13398635 0.81 ALDH1A1 (0.53) GRM6ALDH1A1HPGDMAPTSMN1; SMN2
SCHEMBL20028532 0.81 HPGD (0.53) GRM6ALDH1A1HPGDMAPTSMN1; SMN2
SCHEMBL29790201 0.77 CYP4F2 (0.51) ALDH1A1HPGDMAPTSMN1; SMN2HSD17B10
SCHEMBL937185 0.77 ALDH1A1 (0.71) GRM6ALDH1A1HPGDMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339130-B1 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2022-05-24 US disclosed
US-10934261-B2 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2021-03-02 US disclosed
US-10894776-B2 2021-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10934261-B2 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 GRM6 1343/4885ALDH1A1 4193/4885HPGD 2346/4885
US-10894776-B2 CAPNS1, CAPN9, CAPN2 GRM6 1633/4885ALDH1A1 4421/4885HPGD 2414/4885
US-11339130-B1 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 GRM6 1343/4885ALDH1A1 4193/4885HPGD 2346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.